Pancreatic Cancer Research

ResearcherThe University of OsakaActive in the last 2 years

Yoshiteru Katsura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-9778-1394; OpenAlex author ID A5113797856. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 13

  1. A prospective open label, multicenter phase 2 trial of full-dose gemcitabine and S-1 concurrent with radiation for locally advanced pancreatic ductal adenocarc… Co-author DOI 10.1007/s00595-026-03481-z↗
  2. Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027). Co-author DOI 10.1371/journal.pone.0345459↗
  3. [A Case of Long-Term Survival after Resection of Postoperative Lung Metastasis from Pancreatic Cancer]. Co-author PMID 42178637↗
  4. Safety and feasibility of minimally invasive distal pancreatectomy for pancreatic cancer in elderly patients: A retrospective study. Co-author DOI 10.1111/ases.13331↗
  5. [The Six Cases of Recurrence of Lung Metastasis after Radical Resection of Pancreatic Cancer Performed at Our Hospital]. Co-author PMID 36927912↗
  6. [A Long-Term Survival Case of Locally Advanced Unresectable Pancreatic Adenocarcinoma after Chemoradiotherapy and Conversion Surgery]. Co-author PMID 35045473↗
  7. [A Case Report of Conversion Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastasis after Chemotherapy]. Co-author PMID 31164541↗
  8. [The Treatment Outcomes of FOLFIRINOX for Unresectable and Recurrent Pancreatic Cancer]. Co-author PMID 29394764↗
  9. [Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience]. First author PMID 28133095↗
  10. [Pancreatic Cancer with Liver Metastasis Treated with Radical Surgery after Chemotherapy]. Co-author PMID 28133194↗
  11. [FOLFIRINOX Combination Chemotherapy in Patients with Metastatic or Recurrent Pancreatic Cancer--A Single Institution Experience]. First author PMID 26805364↗
  12. [Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer]. Co-author PMID 26805366↗
  13. [Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience]. Co-author PMID 24393954↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yutaka Takeda · 11 shared papers, 2013–2026 · strength 1.08
  2. Yoshiaki Ohmura · 9 shared papers, 2015–2026 · strength 0.87
  3. Tadafumi Asaoka · 2 shared papers, 2026 · strength 0.50
  4. Yuichiro Doki · 2 shared papers, 2026 · strength 0.50
  5. Yoshifumi Iwagami · 2 shared papers, 2026 · strength 0.50
  6. Kohei Murata · 4 shared papers, 2017–2024 · strength 0.48
  7. Takuya Sakamoto · 5 shared papers, 2016–2023 · strength 0.40
  8. Hidetoshi Eguchi · 1 shared paper, 2026 · strength 0.28
  9. Hidenori Takahashi · 1 shared paper, 2026 · strength 0.28
  10. Shu Okamura · 1 shared paper, 2026 · strength 0.25
  11. Chikato Koga · 1 shared paper, 2026 · strength 0.22
  12. Masahiro Tanemura · 1 shared paper, 2026 · strength 0.22
  13. Masahiro Murakami · 1 shared paper, 2026 · strength 0.22
  14. Masanori Tsujie · 1 shared paper, 2026 · strength 0.22
  15. Hidetoshi Eguchi · 1 shared paper, 2026 · strength 0.22
  16. Hirofumi Akita · 1 shared paper, 2026 · strength 0.22
  17. Yoshito Tomimaru · 1 shared paper, 2026 · strength 0.22
  18. Hiroshi Wada · 1 shared paper, 2026 · strength 0.22
  19. Shigeyuki Tamura · 5 shared papers, 2013–2016 · strength 0.22
  20. Mitsuru Kinoshita · 1 shared paper, 2024 · strength 0.18
  21. Shu Aoyama · 1 shared paper, 2024 · strength 0.18
  22. 村田 幸平 · 1 shared paper, 2021 · strength 0.11
  23. Katsunori Matsushita · 1 shared paper, 2015 · strength 0.04
  24. Yasufumi Sato · 1 shared paper, 2015 · strength 0.04
  25. Rei Suzuki · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.